Kim, Seung Tae; Lee, Jeeyun; Sun, Jong-Mu; Park, Yeon Hee; Ahn, Jin Seok; Park, Keunchil; Ahn, Myung-Ju
Oncology
2010NA ; 79 ( 1-2 ) :78-84.
PMID : 21071994
ÀúÀÚ »ó¼¼Á¤º¸
Kim, Seung Tae -
Lee, Jeeyun -
Sun, Jong-Mu -
Park, Yeon Hee -
Ahn, Jin Seok -
Park, Keunchil -
Ahn, Myung-Ju -
ABSTRACT
PURPOSE: To devise a prognostic model based on clinical parameters for non-small cell lung cancer (NSCLC) patients treated with erlotinib as a salvage therapy. PATIENTS AND
METHODS: Between July 2006 and September 2008, two hundred fifty-seven metastatic/relapsed NSCLC patients who had been treated with erlotinib as a salvage therapy were analyzed retrospectively.
RESULTS: For the 257 patients, the median overall survival (OS) and progression-free survival (PFS) with erlotinib treatment were 12.4 and 2.8 months. Multivariate analysis showed that an ECOG performance status of 2 or more, an elevated serum LDH level, and the absence of skin rash were independent adverse prognostic factors for OS and that the presence of intra-abdominal metastasis, 2 or more prior chemotherapy regimens, and the absence of skin rash were prognostic factors for PFS. Patients were categorized into the following 4 prognosis groups on the basis of each adverse prognostic factor: good, intermediate, poor, and very poor prognosis. The median OS times for the good, intermediate, poor, and very poor prognosis groups were 22.0, 9.3, 5.4, and 2.7 months (p < 0.001) and the median PFS times were 6.5, 3.0, 1.2, and 0.9 months (p < 0.001). CONCLUSION: This prognostic model based on clinical parameters would be useful to identify patients who might be most likely to benefit from erlotinib therapy in clinical practice. CI - Copyright ??2010 S. Karger AG, Basel.
Aged; Analysis of Variance; Antineoplastic Agents/adverse effects/*therapeutic use; Carcinoma, Non-Small-Cell Lung/*drug therapy/secondary; Disease-Free Survival; Drug Eruptions/etiology; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms/*drug therapy/pathology; Male; Middle Aged; *Models, Statistical; Neoplasm Staging; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors/therapeutic use; Quinazolines/adverse effects/*therapeutic use; Retrospective Studies; Salvage Therapy/*methods; Treatment Outcome
MESH
Aged, Analysis of Variance, Antineoplastic Agents/adverse effects/*therapeutic use, Carcinoma, Non-Small-Cell Lung/*drug therapy/secondary, Disease-Free Survival, Drug Eruptions/etiology, Erlotinib Hydrochloride, Female, Humans, Kaplan-Meier Estimate, Lung Neoplasms/*drug therapy/pathology, Male, Middle Aged, *Models, Statistical, Neoplasm Staging, Predictive Value of Tests, Prognosis, Protein Kinase Inhibitors/therapeutic use, Quinazolines/adverse effects/*therapeutic use, Retrospective Studies, Salvage Therapy/*methods, Treatment Outcome
¸µÅ©